Literature DB >> 2866293

Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine.

A Barbeau, T Cloutier, M Roy, L Plasse, S Paris, J Poirier.   

Abstract

It is postulated that Parkinson's disease is the result of environmental factors acting on genetically susceptible individuals against a background of normal ageing. Many potentially neurotoxic xenobiotics are detoxified by hepatic cytochrome P450. The function of one such system was studied in forty patients with Parkinson's disease and forty normal control subjects. Significantly more parkinsonian than control subjects had partially or totally defective 4-hydroxylation of debrisoquine. Poor metabolisers of debrisoquine tended to have had earlier onset of disease.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2866293     DOI： 10.1016/s0140-6736(85)90743-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  31 in total

1.  Poor hydroxylator phenotypes of debrisoquine and S-mephenytoin are not over-represented in a group of patients with Parkinson's disease.

Authors:  O Gudjonsson; E Sanz; G Alván; S M Aquilonius; J Reviriego
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

Review 2.  Inborn 'errors' of drug metabolism. Pharmacokinetic and clinical implications.

Authors:  M S Lennard; G T Tucker; H F Woods
Journal:  Clin Pharmacokinet       Date:  1990-10       Impact factor: 6.447

Review 3.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

4.  Human cytochrome P-450 PB-1: a multigene family involved in mephenytoin and steroid oxidations that maps to chromosome 10.

Authors:  R R Meehan; J R Gosden; D Rout; N D Hastie; T Friedberg; M Adesnik; R Buckland; V van Heyningen; J Fletcher; N K Spurr
Journal:  Am J Hum Genet       Date:  1988-01       Impact factor: 11.025

5.  Ecogenetics, xenobiotic biochemistry and neurological disease.

Authors:  A Williams
Journal:  J Neurol       Date:  1991-07       Impact factor: 4.849

6.  Oxidative polymorphism of debrisoquine in Parkinson's disease.

Authors:  J Benitez; J M Ladero; F J Jimenez-Jimenez; C Martinez; A M Puerto; M J Valdivielso; A Llerena; J Cobaleda; J J Muñoz
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-04       Impact factor: 10.154

7.  A novel cytochrome P-450IID6 (CYPIID6) mutant gene associated with multiple system atrophy.

Authors:  K Iwahashi; R Miyatake; Y Tsuneoka; Y Matsuo; Y Ichikawa; K Hosokawa; K Sato; T Hayabara
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-02       Impact factor: 10.154

8.  Overexpression of CYP2D6 attenuates the toxicity of MPP+ in actively dividing and differentiated PC12 cells.

Authors:  Naomi Matoh; Seigo Tanaka; Masanori Takehashi; Marek Banasik; Todd Stedeford; Eliezer Masliah; Shigehiko Suzuki; Yoshihiko Nishimura; Kunihiro Ueda
Journal:  Gene Expr       Date:  2003

9.  Expression analysis of the mixed function oxidase system in rat brain by the polymerase chain reaction.

Authors:  A V Hodgson; T B White; J W White; H W Strobel
Journal:  Mol Cell Biochem       Date:  1993-03-24       Impact factor: 3.396

10.  CYP2D6, GST-M1 and GST-T1 enzymes: expression in parathyroid gland and association with the parathyroid hormone concentration during early renal replacement therapy.

Authors:  Feng-Xiang Yan; M Chris Langub; Mark A Ihnen; Carlton Hornung; Erkki Juronen; Mary K Rayens; Wei-Min Cai; Peter J Wedlund; Paolo Fanti
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.